News - 02 Jul `20Vitiligo drug candidate goes to the finals of The Nature Spinoff Prize

New

Temprian Therapeutics, a spinoff from Northwestern University with patent for DNA-based vitiligo treatment, has made it to the finals of the Nature Spinoff Prize.

The 12 finalists represent companies from the United States, United Kingdom, Switzerland and Spain operating in pharmaceuticals, predictive assays and medical devices. Temprian’s selection as a finalist for the Nature Spinoff Prize provides hope for securing investment needed for a clinical trial. 

The judges will select four companies to participate in a live slam on 13 July. The winner will be awarded the title of 2020 Nature Spin-off Prize champion — and a grant of €30,000 (about US$34,000).

Details of Temprian’s innovation and its underlying patent Mutant HSP70i to Prevent Autoimmune Disease.

 

      FAQOther Questions

      • Isn't it just a cosmetic disorder?

        Contrary to popular belief, vitiligo is not a cosmetic disorder but a systemic disease affecting the largest body organ and other vital systems, with multiple comorbidities. Fo...

      • What's better: laser or phototherapy?

        In a recent study researchers assessed effect and safety of different laser and phototherapy treatments, such as excimer laser/light, narrowband UVB, UVA and PUVA. No significa...

      • Does halo nevi affect vitiligo development?

        Halo nevi — nevi with an depigmented circle around it, usually on the trunk — are about 10x more common in vitiligo patients than in the general population, especially in childr...